Core Insights - VeraDermics, TG-17, and Colombier Acquisition III went public on February 4, 2026, with significant stock price increases on their debut. Group 1: VeraDermics (MANE) - VeraDermics opened at $34 per share, a 100% increase from the offering price, and closed at $37.75, marking a 122.06% rise with a total market capitalization of $1.259 billion [1][2] - The company issued 15.08 million shares at $17 each, raising $256 million, which will be used for physician education, brand promotion, marketing, infrastructure, and other general corporate purposes [2] - VeraDermics is a late-stage biopharmaceutical company focused on developing innovative therapies for aesthetic and dermatological issues, currently working on an oral, non-hormonal therapy named VDPHL01 for treating PHL [2] Group 2: TG-17 (OBAI) - TG-17 opened at $20 per share, a 60.94% increase, and closed at $33, resulting in a 167.21% rise with a total market capitalization of $457 million [3][6] - The company went public through a direct listing without issuing new shares or raising capital [6] - TG-17 provides AI-driven personal safety services and operates in 28 countries, offering 14 types of monitoring and emergency coordination services [6] Group 3: Colombier Acquisition III (CLBRU) - Colombier Acquisition III issued 26 million units at $10 each, raising $260 million [7] - The company is a special purpose acquisition company (SPAC) initiated by Omeed Malik, focusing on sectors such as technology, advanced manufacturing, defense, energy, and digital infrastructure [7]